MEE N3195-VIII-III, V3.0, Save life. Breathing normally, again. 命を救う 。 再び通常の呼吸をします。
 
"Entake it tonight. Your family members will confirm it works!"
「今夜服用してください。あなたの家族はそれが機能することを確認します!」

Obstructive sleep apnea (OSA) is a common medical condition that occurs in approximately 5% to 15% of the population. The pathophysiology of OSA is characterized by repetitive occlusions of the posterior pharynx during sleep that obstruct the airway, followed by oxyhemoglobin desaturation, persistent inspiratory efforts against the occluded airway, and termination by arousal from sleep. 
 
OSA is a common chronic disorder that is associated with significant morbidity and mortality including cardiovascular, metabolic, and neurocognitive disease and increased cancer-related deaths. OSA is characterized by recurrent episodes of apneas and hypopneas associated with repetitive episodes of intermittent hypoxemia, intrathoracic pressure changes, and arousals. Intermittent hypoxemia (IH) is now being recognized as a potential major factor contributing to the pathogenesis of OSA-related comorbidities. OSA-related high-frequency IH is characterized by cycles of hypoxemia with reoxygenation that is distinctly different than sustained low-frequency hypoxia and contributes to ischemia-reperfusion injury. Data from both animal and human studies support mechanistic links between IH and its adverse impact at the tissue level. IH promotes oxidative stress by increased production of reactive oxygen species and angiogenesis, increased sympathetic activation with BP elevation, and systemic and vascular inflammation with endothelial dysfunction that contributes to diverse multiorgan chronic morbidity and mortality affecting cardiovascular disease, metabolic dysfunction, cognitive decline, and progression of cancer. Data from observational studies in large population groups also support the role for hypoxia in the pathogenesis of OSA comorbidity. Treatment with CPAP to reverse OSA-related symptoms and comorbidities has been shown to provide variable benefit. Early treatment with CPAP makes intuitive sense to promote maximal functional recovery and minimize residual injury. 

MEEOM's Clinically Significant Treatment Response
The MEEOM® approach is inclusive, effective and tailored to the needs of each individual. We do a rigorous assessment with each client at the beginning of treatment, to help us understand the person and the specific problems they want to address through treatment.
 
At MEEOM® Precision Medicine, we provide evidence-based treatment plans that are tailored to the particular needs of each patient.
 
Please send us hospital diagnosis and medical test results.
 
The German Precision Medicine research team of MEEOM® will decide whether to accept the new case within three working days according to the report.
 
より健康的で、より尊敬され、そしてより幸せになります。
Healthier, Wealthier & Happier, MEEOM®.
 
MEEOM® WorldWide Health Systems
MEEOM® Precision Medicine
MEEOM® プレシジョンメディシン
Toll-Free Call 1-833-633-6637 (1833MEEOMER®)
Toll-Free Fax 1-844-633-6637 (1844MEEOMER®) 
meeomers@meeomhealth.club
http://www.meeomhealth.club
3-1-1 Kyobashi
Chuo-ku
Tokyo 104-0031
 
Facts Talk.
事実を話させてください。
 
Copyright© 1999-2023 MEEOM® Precision Medicine
AKA "MEEOM® WorldWide Health Systems"
MEEOM™ “PATTERN”
All U.S. and international rights reserved.
 
References
1. Parish, J et al. Obstructive Sleep Apnea and Cardiovascular Disease
2. Dewan, A et al. Intermittent Hypoxemia and OSA: Implications for Comorbidities, Chest, Volume 147, Issue 1, January 2015
3. Nieto, FJ et al. Sleep-disordered breathing and cancer mortality: results from the Wisconsin Sleep Cohort Study, Am J Respir Crit Care Med, 186 (2012)